EIF4EBP2 and neurodegenerative disease: As such, 4E-BP2 deamidation control is the crucial therapeutic target for neurodegenerative diseases, especially for axons and synapses, which are most vulnerable to neurodegeneration and oxidative stress, where 4E-BP2 deamidation mainly occurs.